Advanced Search

 

Study ID Status Title Patient Level Data
HZA102940 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects Study Listed on ClinicalStudyDataRequest.com
HZA105871 Completed A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HZA108799 Completed A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800 mcg) with and without magnesium stearate, in mild/moderate asthmatic patients. Study Listed on ClinicalStudyDataRequest.com
HZA109895 Terminated An exploratory study to evaluate the response of salmeterol plus fluticasone vs fluticasone alone to experimental nasal inoculation with rhinovirus Study Listed on ClinicalStudyDataRequest.com
HZA109912 Completed A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval Study Listed on ClinicalStudyDataRequest.com
HZC111348 Completed Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
IDB-200-001 Completed A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in subjects between 18-60 and Over 60 Years of Age. Study Listed on ClinicalStudyDataRequest.com
ILI105618 Completed A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin'sLymphoma" Study Listed on ClinicalStudyDataRequest.com
ILI108621 Completed A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer Study Listed on ClinicalStudyDataRequest.com
IPR110723 Completed An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
JNAI-01 Completed A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg for Inhalation or Zanamivir 10 mg for inhalation plus Zanamivir 6.4 mg nasal spray, administered twice daily for 5 days, in the Treatment of Influenza A and B Viral Infections
JNAI-04 Completed A Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zanamivir 10 mg administered Twice Daily (20 mg/day) or 20 mg Twice Daily (40 mg/day) for 5 Days in the Treatment of Influenza A and B Viral Infections, and to Assess the Presence or Absence of Dose-Response Relationship of Zanamivir
JNAI-07 Completed A Double -Blind, Placebo-Controlled Study to Investigate the Therapeutic Effect and Safety of Zanamivir 10 mg Administered Twice Daily (20 mg/day) or 20 mg Administered Twice Daily (40 mg/day) for Five Days in the Treatment of Influenza A and B Infections
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers
L8518 Completed Flexibility in administration of Arixtra for prevention of symptomatic venous thromboembolism in orthopedic surgery
LAM100034 Completed A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures Study Listed on ClinicalStudyDataRequest.com
LAM100036 Completed A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures Study Listed on ClinicalStudyDataRequest.com
LAM10004 Completed An open, randomised, parallel group study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single oral does of new LAMICTAL™ formulations. Study Listed on ClinicalStudyDataRequest.com
LAM10005 Completed A two-part, open label study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single and repeat oral doses of Lamictal SR/XR prototype formulations and to study the effects of food on pharmacokinetic parameters. Study Listed on ClinicalStudyDataRequest.com
LAM100118 Completed An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents Study Listed on ClinicalStudyDataRequest.com
LAM10016 Completed An open-label, non-randomised, single-sequence study to investigate the effects of the combined oral contraceptive pill on the pharmacokinetics of lamotrigine and the effects of lamotrigine on the pharamcokinetics of the combined oral contraceptive pill in healthy young female subjects. Study Listed on ClinicalStudyDataRequest.com
LAM10017 Completed An open-label study in healthy male and female volunteers to evaluate the repeat dose pharmacokinetics and dose strength equivalence of lamotrigine enteric coated modified release tablets over the dose range 25-200 mg. Study Listed on ClinicalStudyDataRequest.com
LAM105379 Completed A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers Study Listed on ClinicalStudyDataRequest.com
LAM20006 Completed A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months) Study Listed on ClinicalStudyDataRequest.com
LAM20007 Completed An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age) Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.